665 related articles for article (PubMed ID: 16261407)
1. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
2. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
Naeim A; Keeler EB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):81-9. PubMed ID: 15607936
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
4. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
Orr RK; Col NF; Kuntz KM
Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
Hillner BE; Smith TJ
N Engl J Med; 1991 Jan; 324(3):160-8. PubMed ID: 1898533
[TBL] [Abstract][Full Text] [Related]
9. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
[TBL] [Abstract][Full Text] [Related]
11. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
13. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
14. [Effective treatment strategy in elderly breast cancer patients].
Boér K
Orv Hetil; 2005 Jan; 146(1):15-21. PubMed ID: 15715368
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
16. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
17. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
18. A model of chemotherapy in node-negative breast cancer.
Hillner BE; Smith TJ
J Natl Cancer Inst Monogr; 1992; (11):143-9. PubMed ID: 1627420
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.
Elkin EB; Weinstein MC; Kuntz KM; Bunnell CA; Weeks JC
Breast Cancer Res Treat; 2005 Sep; 93(1):25-34. PubMed ID: 16184455
[TBL] [Abstract][Full Text] [Related]
20. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]